Ankylosing Spondylitis

You have full text access to this OnlineOpen article

Development and validation of a case ascertainment tool for ankylosing spondylitis

  1. Michael H. Weisman1,¶,*,
  2. Lan Chen2,
  3. Daniel O. Clegg3,
  4. John C. Davis Jr.4,
  5. Robert W. Dubois5,
  6. Pamela E. Prete6,‖,
  7. Laurie M. Savage7,
  8. Laura Schafer8,††,
  9. Maria E. Suarez-Almazor9,‡‡,
  10. Hsing-Ting Yu5,
  11. John D. Reveille10

Article first published online: 28 DEC 2009

DOI: 10.1002/acr.20009

Issue

Arthritis Care & Research

Arthritis Care & Research

Volume 62, Issue 1, pages 19–27, 15 January 2010

Additional Information

How to Cite

Weisman, M. H., Chen, L., Clegg, D. O., Davis, J. C., Dubois, R. W., Prete, P. E., Savage, L. M., Schafer, L., Suarez-Almazor, M. E., Yu, H.-T. and Reveille, J. D. (2010), Development and validation of a case ascertainment tool for ankylosing spondylitis. Arthritis Care Res, 62: 19–27. doi: 10.1002/acr.20009

Author Information

  1. 1

    Cedars-Sinai Medical Center, Los Angeles, California

  2. 2

    Penn Presbyterian Medical Center, Philadelphia, Pennsylvania

  3. 3

    University of Utah, Salt Lake City

  4. 4

    University of California, San Francisco

  5. 5

    Cerner LifeSciences, Beverly Hills, California

  6. 6

    Veterans Administration Healthcare System, Long Beach, California

  7. 7

    Spondylitis Association of America, Sherman Oaks, California

  8. 8

    Seattle, Washington

  9. 9

    University of Texas MD Anderson Cancer Center, Houston

  10. 10

    University of Texas Health Science Center at Houston

  1. Dr. Weisman has received research grants from Abbott, Centocor, and Wyeth, and has received consultant fees from serving on the advisory/data safety monitoring board for Amgen/Wyeth.

  2. ‖

    Dr. Prete has received consultant fees, speaking fees, and/or honoraria (less than $10,000) from UCB.

  3. ††

    Ms Schafer owns stock in Abbott Laboratories.

  4. ‡‡

    Dr. Suarez-Almazor has received consultant fees, speaking fees, and/or honoraria (less than $10,000 each) from BMS, Genentech, and Roche.

*8700 Beverly Boulevard, Suite B-200, Los Angeles, CA 90048

Publication History

  1. Issue published online: 28 DEC 2009
  2. Article first published online: 28 DEC 2009
  3. Manuscript Accepted: 20 AUG 2009
  4. Manuscript Received: 23 MAR 2009

Funded by

  • Spondylitis Association of America
  • Centocor
  • Abbott
  • Amgen
  • Wyeth
  • Pfizer

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (152K)

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Astrid van Tubergen, Ulrich Weber, Diagnosis and classification in spondyloarthritis: identifying a chameleon, Nature Reviews Rheumatology, 2012, 8, 5, 253

    CrossRef

  2. 2
    Martin Rudwaleit, Joachim Sieper, Referral strategies for early diagnosis of axial spondyloarthritis, Nature Reviews Rheumatology, 2012, 8, 5, 262

    CrossRef

  3. 3
    John D. Reveille, Epidemiology of Spondyloarthritis in North America, The American Journal of the Medical Sciences, 2011, 341, 4, 284

    CrossRef

  4. 4
    Charles F. Dillon, Rosemarie Hirsch, The United States National Health and Nutrition Examination Survey and the Epidemiology of Ankylosing Spondylitis, The American Journal of the Medical Sciences, 2011, 341, 4, 281

    CrossRef

  5. 5
    Nick Warde, Ankylosing spondylitis: Development of a new case-ascertainment tool for identifying patients with ankylosing spondylitis, Nature Reviews Rheumatology, 2010, 6, 3, 120

    CrossRef

  6. 6
    Robert A Colbert, Early axial spondyloarthritis, Current Opinion in Rheumatology, 2010, 22, 5, 603

    CrossRef

View Full Article (HTML) Get PDF (152K)